Page 62 - Read Online

Saliba et al. Cancer Drug Resist 2021;4:125-42 I http://dx.doi.org/10.20517/cdr.2020.95 Page 137

11. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement
of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal
abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-65.
12. Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol 2017;35:934-46.
13. Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute
myeloid leukemia. Blood 2010;116:4422-9.
14. Kantarjian H, O’brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid
leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090-8.
15. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J
Med 2018;378:2386-98.
16. Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia
treated with enasidenib. Blood 2019;133:676-87.
17. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J
Med 2017;377:454-64.
18. Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol 2017;18:17.
19. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with
acute myeloid leukemia. Blood 2019;133:7-17.
20. Wei AH, Strickland SA Jr, Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute
myeloid leukemia: results from a phase Ib/II Study. J Clin Oncol 2019;37:1277-84.
21. Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive
chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840-5.
22. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with
newly diagnosed AML with > 30% blasts. Blood 2015;126:291-9.
23. Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients
with acute myeloid leukemia. J Clin Oncol 2010;28:556-61.
24. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient
choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed
acute myeloid leukemia. J Clin Oncol 2012;30:2670-7.
25. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to
chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012;53:110-7.
26. Cidado J, Boiko S, Proia T, et al. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in
Hematologic Cancer Cells. Clin Cancer Res 2020;26:922-34.
27. Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are
ineligible for intensive chemotherapy. Ther Adv Hematol 2019;10:2040620719882822.
28. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med
2020;383:617-29.
29. Braun T, Itzykson R, Renneville A, et al; Groupe Francophone des Myélodysplasies. Molecular predictors of response to decitabine in
advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 2011;118:3824-31.
30. Pleyer L, Germing U, Sperr WR, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on
clinical course and survival. Leuk Res 2014;38:475-83.
31. Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with
vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north american intergroup study SWOG
S1117. J Clin Oncol 2017;35:2745-53.
32. Fenaux P, Mufti GJ, Hellstrom-lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment
of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
33. DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed
and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 2018;93:401-7.
34. Sorm F, Pískala A, Cihák A, Veselý J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964;20:202-3.
35. Gu X, Tohme R, Tomlinson B, et al. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine
metabolism network. Leukemia 2020; doi: 10.1038/s41375-020-1003-x.
36. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2’-deoxycytidine in human cancer cell lines. Blood
2009;113:659-67.
37. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
PLoS One 2010;5:e9001.
38. Leone G, D’Alò F, Zardo G, Voso MT, Nervi C. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr
Med Chem 2008;15:1274-87.
39. Bird AP, Southern EM. Use of restriction enzymes to study eukaryotic DNA methylation. J Mol Biol 1978;118:27-47.
40. McGhee JD, Ginder GD. Specific DNA methylation sites in the vicinity of the chicken beta-globin genes. Nature 1979;280:419-20.
41. Desrosiers RC, Mulder C, Fleckenstein B. Methylation of Herpesvirus saimiri DNA in lymphoid tumor cell lines. Proc Natl Acad Sci U S
A 1979;76:3839-43.